Trials / Terminated
TerminatedNCT06493461
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
Phase 1b, Multicenter, Open-Label, Multiple Ascending Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS135 Added to Background Pulmonary Arterial Hypertension (PAH) Therapy
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- 35Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
Detailed description
Phase 1b, Multicenter, Open-Label, Multiple Ascending Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS135 Added to Background Pulmonary Arterial Hypertension (PAH) Therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HS135 | HS135 is dosed subcutaneously |
Timeline
- Start date
- 2024-10-23
- Primary completion
- 2025-03-31
- Completion
- 2025-03-31
- First posted
- 2024-07-10
- Last updated
- 2025-05-30
Locations
2 sites across 2 countries: Canada, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06493461. Inclusion in this directory is not an endorsement.